Shalby Ltd

Shalby Earnings Call: Key Takeaways

Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.

Shalby Earnings Call: Key Takeaways

Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.

Shalby Other Announcement

Shalby Limited corrected a typographical error regarding its Cost Auditor firm appointment for FY 2026-27. S A & Associates replaces the previously mentioned firm.

Execution

FY 2026-27

Shalby Earnings Call: Key Takeaways

Shalby Limited reports Q4 FY26 consolidated revenue growth of 9.4% YoY. The company is scaling its MedTech implant business and expanding hospital capacity through an asset-light O&M model.

Shalby Earnings Call: Key Takeaways

Shalby Limited delivered Q4 FY26 consolidated revenue growth of 9.4% YoY. Strategy focuses on diversifying specialties beyond arthroplasty and expanding the MedTech implant business.

Shalby Employee Stock Options

Shalby Limited granted 4,000 ESOPs at an exercise price of ₹100 per option. This long-term incentive plan aligns employee interests with shareholder value creation.

Value

₹0.04 Cr

Execution

2 year vesting; 1 year exercise

Shalby Q4 FY26 Results: Turns Profitable, Net Profit ₹18.5 Cr

Shalby Ltd reported revenue from operations of ₹287.4 Cr (+8.5% YoY) and net profit of ₹18.5 Cr for Q4 FY26.

Key figure

Net profit ₹18.5 Cr

Shalby Financial Results

Shalby Ltd reported audited FY2026 standalone revenue of ₹8,985.58 Million. The board did not recommend a dividend and appointed new cost auditors for FY2027.

Shalby Merger & Restructuring

Shalby Limited's step-down subsidiary, Ningen Lifecare, has been struck-off by the MCA. The non-operational entity's closure has no material financial impact on company operations.

Shalby Board Meeting Date

Shalby Ltd scheduled a board meeting on May 27, 2026, to approve audited financial results and recommend a dividend. The trading window remains closed.

Shalby Other Announcement

Shalby Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall compliance with SEBI regulations and guidelines.

Shalby Employee Stock Options

Shalby Limited announced that an employee exercised 7,000 stock options at ₹10 per share, totaling ₹0.007 Crore. The shares will be transferred from the secondary market via the Employee Welfare Trust, resulting in no change to the company's paid-up equity share capital.

Value

₹0.01 Cr

Shalby Management Change

Mr. Vijay Kishanlal Kedia has resigned as an Independent Director of Shalby Limited, effective April 30, 2026. He cited increasing professional commitments and time constraints as reasons for stepping down. The company placed on record its appreciation for his contributions. He confirmed there are no other material reasons for his departure.

Shalby Debt & Borrowing: ₹120.3 Cr

Shalby Limited confirmed it does not qualify as a 'Large Corporate' for the year ended March 31, 2026, under SEBI norms. The company reported outstanding borrowings of ₹120.32 Crore. Consequently, mandatory incremental borrowing requirements through debt securities are not applicable to the company for this period.

Value

₹120.3 Cr

Shalby Regulatory Approval

Shalby Ltd's Krishna unit in Ahmedabad received regulatory approval to perform Kidney Transplants for five years, effective April 9, 2026. This milestone enables the facility to offer comprehensive, life-saving local transplant services, enhancing continuity of care and reducing travel needs for patients in the surrounding community.

Execution

5 years

Shalby Legal & Regulatory

Shalby Limited received an order from the ITAT, Ahmedabad, demanding ₹4.14 Crore. The demand relates to a pre-demerger tax dispute involving share premiums disallowed under Section 68. The company intends to contest the order at appropriate forums and reasonably expects a favorable outcome.

Value

₹4.14 Cr

Shalby Debt & Borrowing: ₹122.1 Cr

Shalby Limited has issued a Standby Letter of Credit (SBLC) for ₹122.08 Crore (USD 13.27 Million) through IndusInd Bank Limited. This guarantee supports its US-based step-down subsidiary, Shalby Advanced Technologies, Inc., in obtaining credit facilities. The company foresees no material financial or operational impact from this contingent liability.

Value

₹122.1 Cr

Shalby Other Announcement

Shalby Limited has submitted its quarterly compliance certificate for the period ended March 31, 2026. Confirmed by KFin Technologies, the filing verifies adherence to SEBI regulations regarding the dematerialization and rematerialization of share certificates. This is a routine regulatory disclosure with no direct financial or operational impact.